Sign in

    Ilya Rachman

    Chief Executive Officer (CEO) and Chairman of the Board of Directors at Immix Biopharma Inc
    Board
    Since 2012
    Age
    53 years
    Education
    Holds a joint MD/PhD degree from the University of Illinois Chicago, an EMBA from the University of California at Los Angeles, and a B.S. from the University of Iowa.
    Tenure
    Has served as founder, Chief Executive Officer, and Chairman of the Board at IMMX since 2012.

    Also at Immix Biopharma Inc

    GM
    Gabriel Morris
    Chief Financial Officer

    About

    Ilya Rachman, MD, PhD, MBA is a pioneering physician/scientist and cell biologist with extensive expertise in oncology and experimental medicine. His career began with significant contributions in clinical research, including establishing a research organization that conducted Phase 3 and 4 trials, and serving at renowned institutions such as Cedars-Sinai Medical Center and UCLA Health.

    Educated at the University of Illinois Chicago, UCLA, and the University of Iowa, he has developed a strong foundation in both academic research and clinical practice. His comprehensive training in medicine and business has enabled him to bridge the gap between scientific innovation and patient care.

    Since founding IMMX in 2012, he has held the roles of Founder, Chief Executive Officer, and Chairman of the Board, driving the company’s strategic initiatives in developing innovative cancer treatments. This leadership role underlines his commitment to leveraging academic research for practical, clinical breakthroughs.

    $IMMX Performance Under Ilya Rachman

    Past Roles

    OrganizationRoleDate RangeDetails
    Clinical Research Organization Founder N/A [N/A]Conducted Phase 3 and Phase 4 clinical trials for major pharmaceutical companies
    Cedars-Sinai Medical Center Physician/Scientist N/A [N/A]Contributed to medical research and clinical practice
    UCLA Health Physician/Scientist N/A [N/A]Participated in clinical research and trained in medicine and research

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Salary$475,000 2024 AnnualBase Salary
    Option Awards$554,658 2024 Grant DateGrant date fair value of option awards
    Stock Options Granted340,000 shares at $2.04/share Issued on June 11, 2024; Vest monthly over 4 years, fully vested on June 11, 2028Outstanding equity award to purchase common stock

    Performance Compensation

    Data from  FY 2024
    Performance MetricWeight (%)Threshold/TargetEvaluation PeriodPayout DetailsAdditional Conditions
    Dose patients in IMX-110 clinical trials20% Achieve set milestone2024Contributes to annual bonus payoutMilestone achieved as determined by Compensation Committee
    Dose patients in NXC-201 clinical trials20% Achieve set milestone2024Contributes to annual bonus payoutMilestone achieved as determined by Compensation Committee
    Complete NXC-201 technology transfer to the U.S.20% Successful transfer2024Contributes to annual bonus payoutMilestone achieved as determined by Compensation Committee
    Manufacture sufficient drug supply for both programs20% Ensure adequate supply2024Contributes to annual bonus payoutMilestone achieved as determined by Compensation Committee
    Complete capital raising and hiring activities20% Secure capital and hire2024Contributes to annual bonus payoutMilestone achieved as determined by Compensation Committee
    Performance Bonus (Cash)N/A50% of Base Salary2024$237,500 cash bonus awarded upon achievement of all milestonesPaid as cash bonus; no vesting applicable